SEC Filing Summary: IGC Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 20, 2023, by India Globalization Capital, Inc. (now IGC Pharma, Inc.), a Maryland corporation. The filing reports a corporate name change effective March 30, 2023, following the filing of Articles of Amendment with the State of Maryland on March 7, 2023. The company's common stock continues to trade on the NYSE American under the symbol "IGC."
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is strictly a notice of corporate governance changes.
Material Changes
- Corporate Name: Changed from "India Globalization Capital, Inc." to "IGC Pharma, Inc."
- Effective Date: The name change is effective March 30, 2023, with trading under the new name commencing March 31, 2023.
- Governance: The Board of Directors approved the Charter and Bylaw Amendments; stockholder approval was not required.
- Identifiers: The CUSIP and Employer Identification Number (EIN) remain unchanged.
- Stock Certificates: Existing certificates reflecting the prior name remain valid and do not need to be exchanged.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management outlook, or discussion of risks and contingencies. The primary purpose is to disclose the name change and the associated amendments to the Articles of Incorporation and Bylaws.
Key Facts for Investor Verification
- Verify the new corporate name "IGC Pharma, Inc." is reflected in trading platforms starting March 31, 2023.
- Confirm that the stock symbol remains "IGC" on the NYSE American.
- Review the attached Articles of Amendment (Exhibit 3.1) and Bylaw Amendment (Exhibit 3.2) for the full legal text of the changes.
- Note that existing stock certificates remain valid despite the name change.